Abstract:In the accompanying paper (Luo et at, cancer Res., 58: 2652-2660, 1998), we demonstrated that vascular endothelial growth factor (VEGF), also designated vascular permeability factor (VPF), significantly accumulated in all mouse malignant ascites tested, suggesting its fundamental role in ascites tumors. Removal of VEGF may inhibit the development of ascites tumors. In this study, using a goat antimouse VEGF-neutralizing antibody, we tested this hypothesis with two well-defined syngeneic mouse ascites tumors: MM2 breast adenocarcinoma and OG/Gardner lymphoma 6C3HED (expressing moderate and low levels of VEGF, respectively). This antibody significantly inhibited MM2 and OG cell-free ascites fluid-induced hyperpermeability of mouse peritoneal microvessels and in vitro endothelial cell growth. Mice hearing tumors were administered i.p. daily with the antibody or normal goat IgG as controls for 8 days, at doses of 20-fold (for MM2-bearing mice) or 40-fold (for OG-bearing mice) the estimated amounts of VEGF that kinetically accumulated in the ascites fluid after the tumor inoculation. The average volume of ascites fluid, number of tumor cells and leaked RBCs, and the peritoneal microvessel permeability in MM2-bearing mice that received the antibody treatment were significantly lower than those in the matched controls (P < 0.01), Unexpectedly, OG-bearing mice did not show satisfactory response to the anti-VEGF treatment. This discrepancy was not likely due to inadequate doses or different host immune responses, but it was quite possibly to the different characteristics of MM2 carcinoma and OG lymphoma tumors, the latter being strongly invasive, and/or the existence of an inflammatory mediator(s), such as bradykinin or cytokine(s) other than VEGF. In summary, our results directly demonstrated, for the first time, differential roles for VEGF in ascites tumors in vivo and suggest the potential of VEGF inhibition as a specific therapy for ascites tumors of carcinoma origin, which are the major cause of the malignant ascites in adult humans.

Control of tumor growth in animals by infusion of an angiogenesis inhibitor.

Effect of Antiangiogenic Therapy on Slowly Growing, Poorly Vascularized Tumors in Mice

Isolations of a cartilage factor that inhibits tumor neovascularization

Identification of an inhibitor of neovascularization from cartilage

Inhibition of Angiogenesis and Breast Cancer Xenograft Tumor Growth by Vegi, A Novel Cytokine of the Tnf Superfamily

Dual Blockade of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF-2) Exhibits Potent Anti-Angiogenic Effects.

Inhibition of Angiogenesis in Rats by IL-1 Receptor Antagonist and Selected Cytokine Antibodies

A Gene Therapy for Cancer Based on the Angiogenesis Inhibitor, Vasostatin.

Targeting neovascularization and respiration of tumor grafts grown on chick embryo chorioallantoic membranes

[Inhibition of K562 Cell Growth and Tumor Angiogenesis in Nude Mice by Antisense VEGF(121) Cdna Transfection].

Efficacy of Dendrimer-Mediated Angiostatin and Timp-2 Gene Delivery on Inhibition of Tumor Growth and Angiogenesis: in Vitro and in Vivo Studies

Differential Inhibition Of Fluid Accumulation And Tumor Growth In Two Mouse Ascites Tumors By An Antivascular Endothelial Growth Factor Permeability Factor Neutralizing Antibody

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers on Lymphangiogenesis of Gastric Cancer in a Nude Mouse Model

The Effect of Antibody Against Vascular Endothelial Growth Factor on Tumor Growth and Metastasis.

Inhibition of Implanting Tumor Growth by Intubation of Powdered Shark Cartilage in Mice and Relationship to Microvascular Density

Data from Context-Dependent Role of Angiopoietin-1 Inhibition in the Suppression of Angiogenesis and Tumor Growth: Implications for AMG 386, an Angiopoietin-1/2–Neutralizing Peptibody

Purification and Characterization of Recombinant Angiogenesis Inhibitor r-K4K5

Edema control by anti-VEGF therapy prolongs survival despite persistent tumor growth in mice

No influence on tumor growth by intramuscular injection of adipose-derived regenerative cells: safety evaluation of therapeutic angiogenesis with cell therapy

Amg 706, An Oral, Multikinase Inhibitor That Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, And Kit Receptors, Potently Inhibits Angiogenesis And Induces Regression In Tumor Xenografts

Scaif80, A Novel Inhibitor of Angiogenesis, and Its Effect on Tumor Growth